Benefit of plasma exchange with albumin replacement on individual items of the quality of life‐Alzheimer’s disease score

Background Alzheimer Management By Albumin Replacement (AMBAR) is a multicenter, randomized, placebo-controlled, Phase IIb/III clinical trial that evaluated the efficacy and safety of Plasma Exchange with replacement (PE-A) in patients mild-to-moderate Alzheimer’s disease (Boada et al., Alzheimers Dement. 2020). PE-A has demonstrated an overall benefit quality life as measured by Quality Life-Alzheimer’s (QoL-AD) score 2021). We treatment for each 13 individual patient-rated QoL-AD items. Method A cumulative logistic mixed model was applied on Full Analysis Set (FAS) population. The odds patient receiving would have more favorable response (i.e., higher item score) than similar subject placebo estimated at final visit item. Age, baseline MMSE score, responses were included covariates. Result FAS 76 229 PE-A-treated patients. significant effect vs. observed 4: Living situation (“How do you feel about place live now?“) [Odds Ratio (OR) = 3.92 (95% CI: 1.38-11.12), p 0.010] 13: Life whole (“When think your whole, everything together, how life?”) [OR 3.80 1.32-10.91), 0.013]. Conclusion analysis when compared to placebo, likely items “Living situation” “Life whole”, suggesting reported full also these